公开(公告)号：US20210093733A1

公开(公告)日：2021-04-01

申请号：US17006881

申请日：2020-08-30

Applicant: OBI Pharma, Inc.

Inventor： Michael Nientse CHANG ,  Ming-Tain LAI ,  Jiann-Shiun LAI ,  Yi-Chien TSAI ,  I-Ju CHEN ,  Wan-Fen LI ,  Kai-Chuan CHEN ,  Teng-Yi HUANG ,  Shu-Yi LIN

IPC: A61K47/68 ,  C07K16/18 ,  A61K45/06 ,  A61P35/00

Abstract: Antibody drug conjugates (ADC's) comprising a drug moiety/payload conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

公开(公告)号：US20210024569A1

公开(公告)日：2021-01-28

申请号：US17041175

申请日：2019-03-27

Applicant: OBI PHARMA, INC.

Inventor： Cheng-Der Tony Yu ,  Yih-Huang Hsieh ,  Wei Han Lee ,  Yu Chen Lin ,  Nan Hsuan Wang

IPC: C07J63/00 ,  A61K39/39 ,  G01N33/15 ,  G01N30/14 ,  G01N30/86 ,  G01N30/74 ,  G01N30/60

Abstract: The present disclosure is related to the six isomer structures (OBI-821-1990-V1A, OBI-821-1990-V1B, OBI-821-1990-V2A, OBI-821-1990-V2B, OBI-821-1858-A, and OBI-821-1858-B) of isolated OBI-821 adjuvant and the method for evaluating the quality thereof. The method of the present disclosure adopts hydrophilic interaction liquid chromatography (HILIC) and reverse phase high performance liquid chromatography (RP-HPLC) either alone or in tandem and is able to separate the isomers of OBI-821 adjuvant in the consequent chromatography. Accordingly, the quality of OBI-821 adjuvant can be further evaluated.

公开(公告)号：US20210017120A1

公开(公告)日：2021-01-21

申请号：US17036588

申请日：2020-09-29

Applicant: OBI PHARMA, INC.

Inventor： Jian-Xin Duan ,  Yeyu Cao ,  Xiaohong Cai ,  Hailong Jiao ,  Jing Yuan Ma ,  Mark Matteucci

IPC: C07C217/58 ,  C07D405/12 ,  C07F9/6558 ,  A61K47/64 ,  C07D403/06 ,  A61K47/55 ,  A61P35/00 ,  C07D239/94 ,  C07D487/04 ,  C07D471/04 ,  C07C213/02 ,  C07D491/22 ,  C07H19/06

Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

公开(公告)号：US20200062861A1

公开(公告)日：2020-02-27

申请号：US16454750

申请日：2019-06-27

Applicant: OBI PHARMA, INC.

Inventor： Cheng-Der Tony YU ,  Yih Huang HSIEH ,  Yin-Cheng HSIEH ,  Teng-Yi HUANG ,  Yi-Chien TSAI ,  Nan-Hsuan WANG ,  Pu-Ling HU

IPC: C07K16/30 ,  C07K16/32 ,  C12N15/85 ,  G01N30/02

Abstract: The present disclosure relates to novel glycosynthase enzymes for glycoprotein engineering and/or homogeneous antibody remodeling. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSd-D232M and EndoSz-D234M can be applied to various mAbs targeting different receptors, including, but not limited to, Globo H, SSEA-4, SSEA-3 series of receptors (OBI-888; Globo H ganglioside), Herceptin (Her 2 receptor), Perjeta (Her 2 receptor) and Vectibix (EGFR receptor). It has been found that both mAb-GlcNAc and mAb-GlucNAc(F) were suitable substrates for both EndoSd-D232M and EndoSz-D234M. The ADCC assay of related products, OBI-888-G2S2 and Herceptin-G2S2, showed that the remodeled homogeneous antibody, mAb-G2S2, has an increased relative activity ranging from 3 to 26 folds.

公开(公告)号：US10364261B2

公开(公告)日：2019-07-30

申请号：US15557053

申请日：2016-03-09

Applicant: OBI PHARMA, INC.

Inventor： Jian-Xin Duan ,  Yeyu Cao ,  Xiaohong Cai ,  Hailong Jiao ,  Jing Yuan Ma ,  Mark Matteucci

IPC: A61K31/396 ,  C07F9/24 ,  G01N33/574

Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

公开(公告)号：US20190225633A1

公开(公告)日：2019-07-25

申请号：US16368753

申请日：2019-03-28

Applicant: OBI PHARMA, INC.

Inventor： Jian-Xin Duan ,  Yeyu Cao ,  Xiaohong Cai ,  Hailong Jiao ,  Jing Yuan Ma ,  Mark Matteucci

IPC: C07F9/24 ,  G01N33/574 ,  A61K31/396

Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

公开(公告)号：US20180193481A1

公开(公告)日：2018-07-12

申请号：US15820309

申请日：2017-11-21

Applicant: OBI Pharma, Inc.

Inventor： Michael Nientse Chang ,  Jiann-Shiun Lai ,  Wan-Fen Li ,  I-Ju Chen ,  Yi-Chien Tsai ,  Kai-Chuan Chen

IPC: A61K47/68 ,  A61P35/00 ,  C08B37/00 ,  A61K45/06 ,  A61K39/395 ,  G01N33/574 ,  A61K51/10 ,  A61K49/16 ,  A61K49/00 ,  A61P35/04 ,  C07K16/18 ,  C07K16/30

CPC classification number: A61K47/6855 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6817 ,  A61K47/6843 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6863 ,  A61K49/0058 ,  A61K49/16 ,  A61K51/1018 ,  A61K51/1051 ,  A61K51/1054 ,  A61K51/1057 ,  A61K51/1063 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61P35/00 ,  A61P35/04 ,  C07K16/18 ,  C07K16/3076 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C08B37/0006 ,  G01N33/57492 ,  A61K2300/00

Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testicle cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

公开(公告)号：US20170304419A1

公开(公告)日：2017-10-26

申请号：US15495470

申请日：2017-04-24

Applicant: OBI PHARMA, INC.

Inventor： Cheng-Der Tony YU ,  Youe-Kong SHUE ,  Chen-Hsin LIANG ,  Peiwen YU ,  Chwen-Cheng CHEN

IPC: A61K39/00 ,  G01N33/574 ,  A61K45/06

CPC classification number: A61K39/0011 ,  A61K45/06 ,  A61K2039/545 ,  A61K2039/55577 ,  A61K2039/575 ,  A61K2039/6081 ,  A61P35/00 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57492 ,  G01N2400/38 ,  G01N2800/52

Abstract: The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against Globo series antigens (i.e., Globo H, Stage-specific embryonic antigen 3 “SSEA3” and Stage-specific embryonic antigen 4 “SSEA4”). Specifically, the method comprises administering Globo H-KLH (OBI-822) in patients with Metastatic Breast Cancer. The disclosure also provides a method of comprises selecting a cancer patient who is suitable as treatment candidate for immunotherapy. In addition, the disclosure provides therapeutic agents, including monoclonal antibodies (mAbs) that bind specifically to Globo series antigens and related biomarkers useful in focusing such therapeutic and diagnostic regimens.

公开(公告)号：US20170283488A1

公开(公告)日：2017-10-05

申请号：US15473267

申请日：2017-03-29

Applicant: OBI Pharma, Inc.

Inventor： Cheng-Der Tony YU ,  Jiann-Shiun LAI ,  I-Ju CHEN ,  Chiu-Chun LIN

IPC: C07K16/18 ,  A61K49/00 ,  G01N33/574 ,  G01N33/92 ,  C12N5/16 ,  A61K39/395

CPC classification number: C07K16/18 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/44 ,  G01N33/57438 ,  G01N33/92 ,  G01N2400/00 ,  G01N2405/10

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

公开(公告)号：US11643456B2

公开(公告)日：2023-05-09

申请号：US16321417

申请日：2017-07-31

Applicant: OBI PHARMA, INC.

Inventor： Cheng-Der Tony Yu ,  Woan Eng Chan ,  Shu-Yu Lee ,  Jiann-Shiun Lai ,  I-Ju Chen

IPC: C07K16/18 ,  A61K47/68 ,  A61K45/06 ,  A61K49/16 ,  G01N33/574 ,  C07K16/44 ,  A61K39/395

CPC classification number: C07K16/18 ,  A61K39/39583 ,  A61K39/39591 ,  A61K45/06 ,  A61K47/6851 ,  A61K49/16 ,  C07K16/44 ,  G01N33/574 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  G01N2400/02

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.